Deregulation of the Ras-mitogen activated protein kinase (MAPK) pathway is an early event in many different cancers and a key driver of resistance to targeted therapies 1 . Sustained signalling through this pathway is caused most often by mutations in K-Ras, which biochemically favours the stabilization of active RAF signalling complexes 2 . Kinase suppressor of Ras (KSR) is a MAPK scaffold 3-5 that is subject to allosteric regulation through dimerization with RAF 6,7 . Direct targeting of KSR could have important therapeutic implications for cancer; however, testing this hypothesis has been difficult owing to a lack of small-molecule antagonists of KSR function. Guided by KSR mutations that selectively suppress oncogenic, but not wild-type, Ras signalling, we developed a class of compounds that stabilize a previously unrecognized inactive state of KSR. These compounds, exemplified by APS-2-79, modulate KSR-dependent MAPK signalling by antagonizing RAF heterodimerization as well as the conformational changes required for phosphorylation and activation of KSR-bound MEK (mitogenactivated protein kinase kinase). Furthermore, APS-2-79 increased the potency of several MEK inhibitors specifically within Rasmutant cell lines by antagonizing release of negative feedback signalling, demonstrating the potential of targeting KSR to improve the efficacy of current MAPK inhibitors. These results reveal conformational switching in KSR as a druggable regulator of oncogenic Ras, and further suggest co-targeting of enzymatic and scaffolding activities within Ras-MAPK signalling complexes as a therapeutic strategy for overcoming Ras-driven cancers.
current drug discovery and development efforts that have focused extensively on direct inhibitors of the Ras effector kinases RAF, MEK, and ERK 14 .
To explore an alternative form of pharmacological modulation and identify Ras-MAPK antagonists via KSR, we focused on large forward genetic screens conducted in flies and worms that identified mutant Rasselective suppressor alleles in KSR [3] [4] [5] . The studies in flies alone evaluated approximately 900,000 randomly mutated strains searching for genetic modifiers of a Ras(G12V)-dependent rough-eye phenotype 15 . We mapped the suppressor alleles onto the primary sequence of KSR (Extended Data Fig. 1a ) and a recently determined X-ray crystal structure of the human KSR2 pseudokinase domain in complex with MEK1 and ATP, and noted a high concentration of suppressor mutations immediately adjacent to the KSR ATP-binding pocket (Fig. 1a ). On the basis of this analysis, we hypothesized that the RAF and MEK interaction interfaces in KSR may be uncoupled through ligands that engage the KSR ATP-binding pocket. Specifically, we speculated that small molecules, which bias KSR towards a state similar to that revealed in the KSR2-MEK1-ATP crystal structure, might function as antagonists of KSR-dependent regulation of RAF and MEK.
To identify active-site-directed ligands of KSR, we screened a collection of 176 structurally diverse kinase inhibitors for direct competition of an activity-based probe (ATP biotin ) that specifically labels the ATPbinding pocket of purified KSR2-MEK1 complexes (Fig. 1b, c) . From this analysis we identified APS-1-68-2 as a competitor of probe-labelling of KSR2-MEK1. This quinazoline-biphenyl ether compound has previously been described as both a Src and epidermal growth factor receptor (EGFR) family kinase inhibitor. Synthetic tailoring of APS-1-68-2 generated highly informative structure-activity relationships (Fig. 1d ). For example, deletion of the terminal phenyl group (APS-1-82-1) or extension of the ether linker (APS-2-12) diminished KSR2-MEK1 probe competition. Notably, addition of a single methyl group at the internal phenyl generated a potent probe compound (APS-2-79; IC 50 of KSR2 = 120 ± 23 nM), whereas the similar dimethyl substituted compound (APS-3-77) was essentially inactive (IC 50 of KSR2 > 10,000 nM).
To assess the biological function of these compounds as Ras-MAPK pathway antagonists, we developed a simplified cell-based reconstitution system to directly monitor KSR-driven MAPK signalling (Fig. 1e ). This system, in which cellular MAPK signalling is dependent on KSR expression, was found to be sensitive to known Ras suppressor mutations in KSR (Fig. 1f ). Likewise, APS-2-79 also suppressed KSR-stimulated MEK and ERK phosphorylation ( Fig. 1g ; P < 0.005 lanes 1 versus 2). The suppression of MAPK signalling by APS-2-79 was dependent on direct targeting of KSR as an active site mutant (KSR(A690F)), which has previously been demonstrated to stimulate KSR-based MAPK outputs independent of ATP-binding 16 , significantly diminished the activity of APS-2-79 ( Fig. 1g ; lanes 5 versus 6, NS; lanes 2 versus 6, P < 0.005). Notably, the negative control for KSR-binding (analogue APS-3-77; see Extended Data Fig. 2b , c for comparative selectivity profiling) was inactive, whereas a positive-control RAF inhibitor, dabrafenib, was active irrespective of the KSR-mutational status (Fig. 1g ). Therefore, on the basis of similarity in phenotype and also direct-binding activity, we identify APS-2-79 as a small-molecule mimic of KSR alleles that suppress oncogenic Ras mutations.
KSR-based activity of APS-2-79 as a MAPK antagonist was further evaluated using reconstitution assays. Dose-dependent phosphorylation of MEK on Ser218/Ser222 by RAF in vitro could be enhanced at least fivefold in the presence of KSR (Extended Data Fig. 3a-c) . KSRstimulated MEK phosphorylation by RAF was markedly reduced by the addition of APS-2-79, but not by APS-3-77 (Extended Data Fig. 3d, e ). APS-2-79 was inactive when KSR was absent or when the KSR2(A690F) mutant was used for in vitro assays (Extended Data Fig. 3d , f, g), suggesting that the activity of APS-2-79 derives from direct targeting of KSR. Indeed, APS-2-79 lacked direct activity against the highly homologous active RAF family kinases, including recombinant BRAF and CRAF, or cellular BRAF(V600E) (Extended Data Figs 2, 3, 4a). Therefore, on the basis of reconstitution and selectivity assays, we conclude that APS-2-79 functions as an antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site.
Notably, we found that a previously described ATP-competitive and active-state binder of KSR termed ASC24 (ref. 7) , in contrast to APS-2-79, did not antagonize KSR-dependent MEK phosphorylation by RAF (Extended Data Fig. 3d, e ), suggesting that inhibition of catalytic activity alone in KSR is insufficient to block MAPK signalling. Consistent with this notion, removal of putative KSR phosphorylation sites 7 in MEK neither impeded MAPK signalling nor blocked the inhibitory activity of APS-2-79 within cells (Extended Data Fig. 4b ).
Previous studies established that genetic suppressors in KSR may impede RAF-induced conformational changes in KSR required for MEK activation or destabilize KSR-MEK and KSR-RAF complexes 6,7,12,17-19 . To distinguish between such possible modes of action, we determined an X-ray crystal structure of the KSR2-MEK1 complex bound to APS-2-79 ( Fig. 2a ). In the APS-2-79-bound state, KSR2 binds MEK1 in a 1:1 fashion within a quaternary arrangement that is nearly identical to the ATP-bound state of KSR2-MEK1 complexes 7 (Extended Data Fig. 5 ). Within both states, KSR2 and MEK1 bind via a face-to-face arrangement mediated largely through reciprocal helix α G and activation segment interactions, and KSR2 homodimerizes through the N-lobe along a crystallographic two-fold symmetry axis producing a hetero-tetramer of KSR2-MEK1 dimers.
In the APS-2-79-bound state, only KSR2 was found to possess strong electron density that could be assigned to APS-2-79 (Extended Data Fig. 6a, b ). Two portions of APS-2-79 engage distinct regions in KSR2. First, the biphenyl ether extends to a sub-pocket within KSR2, defined by Thr739, Arg692, Asp803 and a hydrophobic shell composed of Phe725, Tyr714 and Phe804 (Fig. 2b, c) . Stacking interactions between the terminal phenyl in APS-2-79, and Phe725, Tyr714 and Phe804 in particular are expected to provide strong interactions between KSR2 and APS-2-79 through the arrangement of a four-member aromaticpair network (Fig. 2b, c) . The existence of this network was substantiated by removal of the terminal phenyl in APS-2-79-like compounds, which greatly diminished competition of ATP biotin probe-labelling in KSR2 (Extended Data Fig. 7 ; APS-1-68-2 versus APS-1-70-1 and APS-1-82-1). This network of aromatic-pair interactions, in addition to other amino acid substitutions, probably contributes to the selectivity of APS-2-79 for KSR over RAF (Extended Data Fig. 6c, e ). Second, a hydrogen bond between the N1 in the quinazoline core of APS-2-79 and the leads to enhanced MAPK signalling within 293H cells, as visualized by immunoblotting for phosphorylated MEK and ERK. f, MAPK activation is sensitive to known genetic suppressor mutations in KSR. A690F is a KSR mutant predicted to signal independent of ATP-binding 16 . W884D is a loss-of-function mutation predicted based on structural analysis. Note, human KSR2 numbering used here and throughout. g, APS-2-79 impedes KSR-stimulated MAPK signalling within cells by wild-type KSR but not a control mutant (KSR(A690F)). Cells were treated with 5 μ M of APS-2-79, APS-3-77, or dabrafenib for 2 h. In e-g, cells were collected for western blot analysis 24 h after transfection. Error bars indicate the mean ± s.d. (n = 3 biological replicates). Signals were normalized relative to lane 1 (e and g) or 3 (f). NS, not significant. * * * P < 0.0005 by two-tailed unpaired t-testing.
Letter reSeArCH
backbone at Cys742 further mediates APS-2-79-KSR2 interactions. Notably, functionalization of the N1 with a methyl group (APS-3-6) greatly diminished KSR2-MEK1 activity, whereas replacement of the N3 with -CH (APS-2-16) was moderately tolerated (Extended Data Fig. 7 ). Therefore, on the basis of crystallographic analysis and also structure-activity relationships data from our analogue series, APS-2-79 binds directly to KSR2 within the KSR2-MEK1 complex.
In both the APS-2-79-and ATP-bound states of KSR2-MEK1, KSR2 directly engages the activation segment of MEK1, burying the Ser218-Ser222 region and presumably shielding this segment of MEK from promiscuous phosphorylation. The KSR2-MEK1-APS-2-79 structure revealed a portion of KSR2 that was not previously modelled in the ATPbound complex (Extended Data Fig. 6d ). This region, encompassing residues Ile809 to Gln814, which we refer to as the induced lock, forms an extension of the activation segment C terminus to the conserved DFG motif, and forms an anti-parallel β -strand with the peptide sequence centred around Arg823 in KSR2 ( Fig. 2d ). Additionally, the ordering of residues Ile809 to Gln814 in KSR2 occurs at the expense of disorder of residues 674 to 676 in the P-loop, which in the ATP-bound state directly coordinates the β and γ phosphates ( Fig. 2e ). The two modes by which ATP and APS-2-79 affect KSR-based interactions on MEK appear mutually exclusive as both ligands induce conformations that would otherwise clash with one another ( Fig. 2e ). We interpret these structures to suggest that APS-2-79 stabilizes an inactive state of KSR2 characterized by reinforcement of negative regulatory interactions. Indeed, APS-2-79 behaves as a KSR-dependent antagonist of RAF-mediated MEK phosphorylation by shifting the equilibrium of KSR-MEK complexes so as to populate the OFF state (Extended Data Fig. 5c ).
Comparison of the ATP-bound and APS-2-79-bound states of KSR2-MEK1 suggested that APS-2-79 antagonizes RAF phosphorylation on MEK indirectly by impeding KSR-RAF heterodimers. As well as APS-2-79 binding, the dimer interface of KSR2, including residues Trp685 and His686, demonstrated perturbations relative to the ATP-bound conformation ( Fig. 3a , Extended Data Fig. 8 ). To investigate directly the effect of APS-2-79 on KSR2-BRAF dimerization, we used bio-layer inferometry (BLI) to monitor real-time association and dissociation of KSR2-MEK1 or free MEK1 to a sensor tethered with immobilized BRAF. In control experiments, we found that KSR2-MEK1 complexes did not associate with immobilized BRAF in a 1:1 fashion ( Fig. 3b ), probably owing to the formation of higher order BRAF-KSR2-MEK1 complexes. In contrast, BRAF bound to free MEK1 in a 1:1 fashion with a dissociation constant (K d ) = 51 ± 3.8 nM ( Fig. 3c ), which is in close agreement to published work 20 .
To specifically monitor KSR2-BRAF dimerization relative to other possible interactions, we identified a mutation in BRAF(F667E) that eliminates binding to free MEK but not KSR2-MEK1 complexes ( Fig. 3d, e ). KSR2-MEK1 interacted in a 1:1 fashion with the BRAF(F667E) mutant with a K d of 1.99 ± 0.09 μ M; closely matching previously published BRAF-BRAF dimerization values 6 . Notably, the addition of a secondary mutation, known to perturb KSR2-BRAF dimers (BRAF(F667E/R509H); Fig. 3f ), completely abrogated any binding signal between KSR2-MEK1 and BRAF. In the presence of APS-2-79, the KSR2-BRAF(F667E) dimers did not associate ( Fig. 3g) , consistent with the prediction of the crystal structure suggesting that APS-2-79 may impede RAF-KSR dimers. In contrast, the control compound APS-3-77 did not impede KSR2-BRAF interactions (Extended Data Fig. 8c ). Therefore, we conclude that BRAF can dimerize with KSR2-MEK1 complexes directly via KSR2, and this interaction is antagonized by APS-2-79.
Ras mutations occur in approximately 25% of all cancer patients and are highly associated with poor response to therapy 1 . Significant progress has been made in targeting BRAF(V600E)-mutant melanoma, however RAF and MEK inhibitors have failed to achieve significant clinical efficacy in Ras-mutant disease owing in part to mechanisms of inhibitor-induced transactivation and feedback, respectively 21 . MEK-inhibitor feedback has been characterized by upstream Ras activation and induction of higherorder RAF-RAF and also RAF-KSR complexes [22] [23] [24] . In an engineered cell system, we found that a Ras-suppressor allele (R718H 6,7 ) within KSR reduced MEK inhibitor-induced feedback (Extended Data Fig. 4c ), suggesting the possibility that KSR heterodimerization may limit the efficacy of MEK inhibitors. Owing to the more pronounced role of KSR in Ras-mutant, as opposed to RAF-mutant signalling 15, 25 , and the ability of APS-2-79 to impede KSR-RAF heterodimerization, we hypothesized that stabilization of the KSR-inactive state (KSRi) via APS-2-79 may potentiate the effect of MEK inhibitors by limiting feedback in Ras-mutant models. We therefore tested for synergy of APS-2-79 with MEK inhibitors in Ras-mutant cell lines, and used RAF-mutant cell lines as controls. 70 78 73  2 0 1 0 14 10 29 51 68 75  5 6 11 16 32 51 64 73 80 84  14 15 18 27 40 56 67 76 82 83   0 0 7 11 10 21 34 38 44 51  1 4 9 14 19 29 47 47 55 58  0 3 12 18 20 36 45 54 60 60  1 13 24 33 38 45 49 49 60 61  54 48 56 61 58 64 63 63 72 67   0 13 19 40 54 70 72 75 82 
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We found that APS-2-79 shifted the cell viability dose response to trametinib in Ras-mutant cell lines HCT-116 and A549, but not BRAF mutant cell lines SK-MEL-239 and A375 (Fig. 4a ). Although the cellular effects of APS-2-79 alone were modest, combination analysis over full concentration matrices revealed that KSRi synergizes with trametinib, and other MEK inhibitors (Extended Data Fig. 9a ), specifically in KRAS mutant cell lines (Fig. 4b) . APS-3-77, and additional control compounds (Extended Data Fig. 9b and 10) , did not demonstrate Ras-mutant-specific synergy, supporting the hypothesis that the enhanced activity of trametinib when combined with APS-2-79 depends on co-modulation of KSR. To determine the possible mechanism for APS-2-79 and trametinib synergy, we examined MAPK signalling and found that APS-2-79 treatment caused a twofold enhancement in the IC 90 of trametinib on ERK phosphorylation in the Ras-mutant HCT-116 cell line but not the RAF-mutant SK-MEL-239 cell line (Fig. 4c, Extended Data Fig. 4d ). The data presented here provide proofof-concept for the use of KSRi to overcome a key liability of a clinical MEK inhibitor in K-Ras mutant cells. Indeed, we posit stabilization of the KSRi as a mechanism to impede feedback activated Ras-MAPK signalling induced by MEK inhibition (Fig. 4d ).
Here we have identified a unique conformation in KSR through the discovery of APS-2-79. This compound offers a foundation for the development of a new class of targeted therapies based on stabilization of the KSR inactive state. Future efforts will be directed towards improving the pharmacological properties of APS-2-79 to enable in vivo and clinical studies. In general, the stabilization of conformational states with small-molecule modulators may be an effective strategy to target other pseudokinases 26, 27 . Furthermore, the results presented here, using KSRi in combination with clinical MEK inhibitors, suggests a mechanism to improve the efficacy of inhibitors that target enzymatically active kinases through co-modulation of pseudokinase-active kinase signalling complexes.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Extended Data Figure 1 | Projection of Ras(G12V) suppressor alleles onto the primary and tertiary structure of KSR. a, Schematic representation of KSR from Drosophila, Caenorhabditis elegans, and KSR1 or KSR2 from humans. Suppressor mutations within KSR identified from forward genetic screens are highlighted with red stars. Allele names and corresponding mutations are given [3] [4] [5] 15 . Two alleles in KSR found in the Drosophila screen are shown; one encoding for substitutions in a coil-coil SAM domain (CC-SAM) at the N terminus of Drosophila KSR (S548) and a second mutant in the predicted ATP-binding pocket of the KSR pseudokinase domain (S638). Eight distinct alleles were described in two separate studies conducted in C. elegans. The vast majority of the mutants localize to the pseudokinase domain of KSR and in particular ATP-contact residues (yellow). Residues highlighted in red and shown in the lower panel correspond to the human KSR2 residue equivalents of suppressor mutations found in Drosophila and C. elegans orthologues. b, KSR is a scaffold for the Ras-MAPK signalling pathway. Phosphorylation of MEK1/2 at Ser218 and Ser222 by RAF, or ERK1/2 via phosphorylation at Thr202 and Tyr204 by MEK, are key events in signalling through the Ras-MAPK signalling pathway. c, Purification of the KSR2-MEK1 complex from insect cells. The KSR2 pseudokinase domain (KSR2(KD)) and MEK1 were co-expressed using the SF21 insect cell system. Lysis was performed by one freeze-thaw and sonication. Lysates were incubated with cobalt resin for 2 h and KSR2(KD)-MEK1 was eluted using a highimidazole buffer. Eluate was then incubated with tomato etch virus (TEV) protease and λ -phosphatase overnight. The mixture was then applied to an ion-exchange column (Sp-HP) to separate stoichiometric KSR2-MEK1 complexes from free MEK1 and TEV. Fractions containing KSR2-MEK1 were applied to a gel-filtration column for final purification. d, Schematic of the ATP biotin probe-labelling assay on KSR2-MEK1 complexes and screen for inhibitors. e, ATP biotin directly labels KSR2 and MEK1 within purified complexes. Deconvoluted mass spectrum for KSR2-MEK1 complexes incubated with ATP biotin . KSR2 and MEK1 spectra are included in the top and bottom panels, respectively. f, Graphical representation for ATP biotin probe-labelling of KSR2-MEK1 complexes in the presence of increasing free ATP as shown in Fig. 1b . Corresponding IC 50 values listed for both KSR2 and MEK1. arrows. Thr802 in KSR2, which is universally a Gly residue in all active RAF homologues, and also Phe516 and Phe793 in KSR2, which adopt distinct orientations from the equivalent Phe residues in RAF kinases, directly contact the biphenyl ether motif in APS-2-79. The T802G substitution, as well as the positional differences of the above-mentioned aromatic residues, would be predicted to reduce binding of active RAFs with APS-2-79. Another interaction that is probably favoured in KSR includes the contact mediated by the epsilon nitrogen of Arg692 with the -O-linker of the biphenyl motif; the placement of Arg692 is stabilized by Asp803 of the DFG motif. In RAF, the Arg-to-Lys substitution (Lys483 in subdomain II of BRAF), lacks the equivalent nitrogens to bond with both the -O-linker in APS-2-79 and the aspartate of the DFG motif. d, Positive (blue) and negative (red) F o − F c electron density map contoured at ± 2.5σ, before modelling of residues I809 to Q814 in KSR2, is shown. e, Sequence alignment of KSR and RAF proteins. Arrows highlight APS-2-79 contact residues. 

